Keywords: Merck & Co, Janacti, Combination, Sitagliptin, Pioglitazone, Type 2 diabetes, Vorapaxar, Thrombosis
Merck & Co drops combo diabetes drug Janacti filing in Europe; presents data on discontinued vorapaxar study
Article | 15 November 2011
The European Medicines Agency says it has been formally notified by Merck Sharp & Dohme (Europe), a subsidiary of US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
